Current Issue

View Larger Image

Past Issues Adlink Subscription Visit Our Publisher

ADVERTISEMENT



Top Keywords




GEN News Highlights: Back to Item

Celator Pockets $20M to Progress Phase II Combination Therapy for Cancer

CPX-351 couples cytarabine and daunorubicin and maintains their synergistic activity after administration.



Click here to log in or to register for free.

You will be taken back to your selected item after log-in/registration.

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

Funding Early-Stage Companies

How much do you think newly established funds will succeed in helping startups?

Suggest a Poll